Apollo Hospitals

  • Market Cap: Large Cap
  • Industry: Hospital
  • ISIN: INE437A01024
  • NSEID: APOLLOHOSP
  • BSEID: 508869
INR
8,838.50
38.5 (0.44%)
BSENSE

Aug 28, 03:30 PM

BSE+NSE Vol: 3.26 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

3.26 lacs (19.33%) Volume

Shareholding (Jun 2026)

FII

41.50%

Held by 1202 FIIs

DII

23.94%

Held by 118 DIIs

Promoter

28.02%

Why is Apollo Hospitals Enterprise Ltd. falling/rising?

29-Aug-2026

As of 28-Aug, Apollo Hospitals Enterprise Ltd. is seeing a stock price increase to 8,845.70, driven by strong momentum and increased investor interest, evidenced by a rise in delivery volume. The company also shows solid financial performance with consistent profit growth and a favorable Return on Capital Employed.

As of 28-Aug, Apollo Hospitals Enterprise Ltd. is experiencing a rise in its stock price, currently at 8,845.70, with an increase of 40.2 (0.46%). This upward movement can be attributed to several positive factors. The stock has been gaining for the last two days, with a return of 0.63% during this period. Furthermore, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating strong momentum.<BR><BR>Investor participation has also increased, as evidenced by a delivery volume of 1.87 lacs on 27 August, which is up by 22.96% compared to the 5-day average. This suggests growing interest and confidence among investors. The stock's liquidity is adequate, allowing for trades of significant size, which further supports its price stability and growth.<BR><BR>Financially, Apollo Hospitals demonstrates strong management efficiency with a high Return on Capital Employed (ROCE) of 17.13% and consistent growth in net sales and operating profit. The company has reported positive results for 11 consecutive quarters, with a net profit growth of 10.31% and record figures in net sales and operating profit. Additionally, the stock is trading at a discount compared to its peers, enhancing its attractiveness to investors.<BR><BR>Overall, the combination of positive performance metrics, increased investor participation, and strong financial results contributes to the rising stock price of Apollo Hospitals Enterprise Ltd.

View full answer

Should I buy, sell or hold Apollo Hospitals Enterprise Ltd.?

26-Aug-2026

Who are in the management team of Apollo Hospitals?

14-Aug-2026

The management team of Apollo Hospitals includes Prathap C Reddy (Executive Chairman), Preetha Reddy (Executive Vice Chairperson), Suneeta Reddy (Managing Director), and Sangita Reddy (Joint Managing Director), along with several independent directors. This team is responsible for guiding the strategic direction and operations of the organization.

The management team of Apollo Hospitals includes the following key members:<BR><BR>1. **Prathap C Reddy** - Executive Chairman<BR>2. **Preetha Reddy** - Executive Vice Chairperson<BR>3. **Suneeta Reddy** - Managing Director<BR>4. **Sangita Reddy** - Joint Managing Director<BR>5. **Shobana Kamineni** - Executive Vice Chairperson<BR>6. **S M Krishnan** - Senior Vice President & Company Secretary<BR><BR>Additionally, the board includes several independent directors:<BR>- **Vinayak Chatterjee**<BR>- **Murali Doraiswamy**<BR>- **V Kavitha Dutt**<BR>- **M B N Rao** - Lead Independent Director<BR>- **Som Mittal**<BR>- **Rama Bijapurkar**<BR><BR>This team plays a crucial role in guiding the strategic direction and operations of Apollo Hospitals.

View full answer

What does Apollo Hospitals do?

14-Aug-2026

Apollo Hospitals Enterprise Ltd. is a leading private healthcare provider in Asia, with recent net sales of ₹7,044 Cr and a net profit of ₹581 Cr as of June 2026. It has a market cap of ₹124,234 Cr and key metrics include a P/E ratio of 59.00 and a return on equity of 20.63%.

Overview: <BR>Apollo Hospitals Enterprise Ltd. is a leading private sector healthcare provider in Asia, operating within the hospital industry and categorized as a large-cap company.<BR><BR>History: <BR>Apollo Hospitals Enterprise Ltd. was incorporated in an unspecified year and has maintained its status as a prominent healthcare provider. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 7,044 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 581 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 124,234 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 59.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.23% <BR>Debt-Equity: 0.67 <BR>Return on Equity: 20.63% <BR>Price to Book: 12.99<BR><BR>Contact Details: <BR>Address: No 19 Bishop Garden, Raja Annamalaipuram Chennai Tamil Nadu : 600028 <BR>Phone: 91-44-28290956/28293896 <BR>Email: apolloshares@vsnl.net <BR>Website: http://www.apollohospitals.com

View full answer

Who are the peers of the Apollo Hospitals?

14-Aug-2026

Apollo Hospitals' peers include Max Healthcare, Aster DM Quality, Fortis Health, Global Health, Narayana Hrudaya, Krishna Institute, Dr. Agarwal's Health, and Rainbow Child. Apollo Hospitals shows good management risk and excellent growth, with a 1-year return of 10.07%, while Aster DM Quality leads with 34.49% and Max Healthcare has the lowest at -20.39%.

Peers: The peers of Apollo Hospitals are Max Healthcare, Aster DM Quality, Fortis Health., Global Health, Narayana Hrudaya, Krishna Institu., Dr Agarwal's Hea, and Rainbow Child.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Global Health, Narayana Hrudaya, and Rainbow Child, while Good management risk is found at Apollo Hospitals, Aster DM Quality, Krishna Institu., and Dr Agarwal's Hea. Average management risk is present at Fortis Health. and the rest. For growth, Excellent growth is seen at Apollo Hospitals, Max Healthcare, and Narayana Hrudaya, while Good growth is found at Fortis Health., Dr Agarwal's Hea, and the rest. Below Average growth is noted at Aster DM Quality, Krishna Institu., and Rainbow Child. In terms of Capital Structure, Excellent capital structure is present at Max Healthcare and Global Health, while Average capital structure is found at Apollo Hospitals and Aster DM Quality, and Good capital structure is seen at Fortis Health., Narayana Hrudaya, Krishna Institu., Dr Agarwal's Hea, and Rainbow Child.<BR><BR>Return Snapshot: Apollo Hospitals has a 1-year return of 10.07%, while Aster DM Quality has the highest return at 34.49% and Max Healthcare has the lowest return at -20.39%. Apollo Hospitals' return is significantly higher than Max Healthcare's. Additionally, the six-month returns for Max Healthcare, Narayana Hrudaya, and Fortis Health. are negative.

View full answer

How big is Apollo Hospitals?

14-Aug-2026

As of 14th August, Apollo Hospitals Enterprise Ltd. has a market capitalization of 128,284.67 Cr, with recent net sales of 26,429.90 Cr and a net profit of 2,089.50 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Apollo Hospitals Enterprise Ltd. has a market capitalization of 128,284.67 Cr, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 26,429.90 Cr, while the sum of Net Profit for the same period is 2,089.50 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2026. Shareholder's Funds are valued at 9,480.10 Cr, and Total Assets amount to 22,182.80 Cr.

View full answer

Are Apollo Hospitals Enterprise Ltd. latest results good or bad?

21-May-2026

Apollo Hospitals Enterprise Ltd. reported strong results for the March 2026 quarter, with net sales of ₹6,605.50 crores and a net profit of ₹529.30 crores, reflecting significant year-on-year growth and improved operational efficiency. Overall, the results are considered good, showcasing the company's solid performance in the healthcare sector.

Apollo Hospitals Enterprise Ltd. has reported strong results for the March 2026 quarter, indicating good performance. The company achieved net sales of ₹6,605.50 crores, reflecting a sequential growth of 1.98% and an impressive year-on-year increase of 18.12%. This marks an all-time high for net sales, showcasing Apollo's ability to expand its operations effectively.<BR><BR>The net profit for the quarter stood at ₹529.30 crores, which is a 5.38% increase compared to the previous quarter and a significant 35.86% increase year-on-year. Additionally, the operating margin improved to 15.31%, the highest in recent quarters, indicating enhanced operational efficiency.<BR><BR>Overall, Apollo Hospitals' financial performance demonstrates consistent growth, strong profitability metrics, and effective cost management, positioning the company favorably within the healthcare sector. The results can be considered good, reflecting the company's solid execution capabilities and favorable industry dynamics.

View full answer

When is the next results date for Apollo Hospitals Enterprise Ltd.?

05-May-2026

The next results date for Apollo Hospitals Enterprise Ltd. is 20 May 2026.

The next results date for Apollo Hospitals Enterprise Ltd. is scheduled for 20 May 2026.

View full answer

Has Apollo Hospitals Enterprise Ltd. declared dividend?

12-Feb-2026

Yes, Apollo Hospitals Enterprise Ltd. has declared a dividend of 200%, amounting to ₹10 per share, with an ex-date of February 16, 2026. The dividend yield is 0.25%, contributing to positive total returns across various periods.

Apollo Hospitals Enterprise Ltd. has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 10<BR>- Ex-date: 16 Feb 26<BR><BR>Dividend Yield: 0.25%.<BR><BR>Total Returns by Period:<BR>In the 3 Months period, the price return was 0.52%, the dividend return was 0.13%, resulting in a total return of 0.65%.<BR><BR>In the 6 Months period, the price return was 4.21%, the dividend return was 0.25%, leading to a total return of 4.46%.<BR><BR>In the 1 Year period, the price return was 17.92%, the dividend return was 0.32%, culminating in a total return of 18.24%.<BR><BR>In the 2 Years period, the price return was 13.99%, the dividend return was 0.58%, resulting in a total return of 14.57%.<BR><BR>In the 3 Years period, the price return was 70.71%, the dividend return was 1.23%, leading to a total return of 71.94%.<BR><BR>In the 4 Years period, the price return was 66.7%, the dividend return was 1.54%, culminating in a total return of 68.24%.<BR><BR>In the 5 Years period, the price return was 174.48%, the dividend return was 2.57%, resulting in a total return of 177.05%.<BR><BR>Overall, Apollo Hospitals Enterprise Ltd. has declared a significant dividend, which contributes to its total returns across various periods, indicating a strong performance in both price appreciation and dividend distribution.

View full answer

Is Apollo Hospitals technically bullish or bearish?

04-Dec-2025

As of December 3, 2025, Apollo Hospitals shows a mildly bearish trend, driven by bearish signals from the MACD, KST, and OBV on weekly and monthly charts, despite some mixed indicators from Bollinger Bands and daily moving averages.

As of 3 December 2025, the technical trend for Apollo Hospitals has changed from sideways to mildly bearish. The current technical stance is mildly bearish. Key indicators driving this stance include the MACD on both weekly and monthly time frames showing mildly bearish signals, along with the KST and OBV also indicating mild bearishness on the weekly and monthly charts. The Bollinger Bands present a mixed view, being bearish on the weekly but mildly bullish on the monthly. The daily moving averages suggest a mildly bullish position, but this is overshadowed by the overall bearish indicators in the longer time frames.

View full answer

How has been the historical performance of Apollo Hospitals?

24-Nov-2025

Apollo Hospitals has shown consistent growth in net sales and profitability, with net sales increasing from 9,617.44 Cr in Mar'19 to 21,794.00 Cr in Mar'25, and profit after tax rising from 199.18 Cr to 1,472.10 Cr in the same period. The company has also improved its earnings per share from 16.97 to 100.55 and demonstrated strong asset growth.

Answer:<BR>The historical performance of Apollo Hospitals shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Apollo Hospitals has demonstrated significant growth in net sales, increasing from 9,617.44 Cr in Mar'19 to 21,794.00 Cr in Mar'25. The total operating income followed a similar trend, reaching 21,794.00 Cr in Mar'25, up from 16,612.50 Cr in Mar'23. The operating profit (PBDIT) also rose notably, from 1,095.10 Cr in Mar'19 to 3,222.10 Cr in Mar'25, reflecting an operating profit margin of 13.87% in the latest year. Profit before tax surged to 2,006.10 Cr in Mar'25, with profit after tax reaching 1,472.10 Cr, marking a significant increase from 199.18 Cr in Mar'19. The earnings per share (EPS) improved dramatically from 16.97 in Mar'19 to 100.55 in Mar'25. On the balance sheet, total assets grew from 11,288.80 Cr in Mar'20 to 20,644.30 Cr in Mar'25, while total liabilities increased from 11,288.80 Cr to 20,644.30 Cr in the same period. Cash flow from operating activities has also shown positive growth, reaching 2,136.00 Cr in Mar'25, contributing to a closing cash balance of 578.00 Cr. Overall, Apollo Hospitals has exhibited robust financial performance with increasing revenues, profits, and asset growth over the years.

View full answer

Is Apollo Hospitals overvalued or undervalued?

31-Oct-2025

As of October 30, 2025, Apollo Hospitals is considered undervalued with an attractive valuation grade, featuring a PE ratio of 71.16, a lower PEG ratio of 1.37 compared to peers, and an 11.30% return over the past year, outperforming the Sensex's 5.58%.

As of 30 October 2025, Apollo Hospitals has moved from a fair to an attractive valuation grade, indicating a shift in its perceived value. The company is currently considered undervalued, particularly when compared to its peers. Key ratios include a PE ratio of 71.16, an EV to EBITDA of 36.59, and a ROE of 17.61%. <BR><BR>In comparison to its peers, Apollo Hospitals stands out with a lower PEG ratio of 1.37, while competitors such as Max Healthcare and Fortis Health are deemed very expensive with PE ratios of 94.85 and 85.21, respectively. Additionally, despite a slight decline in the past week, Apollo Hospitals has outperformed the Sensex over the past year with a return of 11.30% compared to the Sensex's 5.58%, reinforcing its attractive valuation in the current market.

View full answer

Who are the top shareholders of the Apollo Hospitals?

17-Jul-2025

The top shareholders of Apollo Hospitals include M/s. Pcr Investments Ltd with 18.93%, Foreign Institutional Investors holding 43.49%, and mutual funds with 15.94%. The highest public shareholder is Mirae Asset Midcap Fund at 2.21%, while individual investors own 3.98%.

The top shareholders of Apollo Hospitals include a mix of institutional and individual investors. The largest shareholder is M/s. Pcr Investments Ltd, which holds 18.93% of the company. Foreign Institutional Investors (FIIs) are significant stakeholders, collectively holding 43.49%. Additionally, mutual funds are represented by 324 schemes, accounting for 15.94% of the shares. The highest public shareholder is Mirae Asset Midcap Fund, with a holding of 2.21%. Individual investors collectively own 3.98% of the company.

View full answer
iScoreScore
Part of MojoOne Strategy
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROCE of 17.13%

 
2

Healthy long term growth as Net Sales has grown by an annual rate of 16.82% and Operating profit at 23.85%

 
3

With a growth in Net Profit of 10.31%, the company declared Very Positive results in Jun 26

4

With ROCE of 18.3, it has a Attractive valuation with a 8.4 Enterprise value to Capital Employed

5

High Institutional Holdings at 65.44%

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Hospital

stock-summary
Market cap

INR 127,321 Cr (Large Cap)

stock-summary
P/E

60.00

stock-summary
Industry P/E

68

stock-summary
Dividend Yield

0.23%

stock-summary
Debt Equity

0.67

stock-summary
Return on Equity

20.63%

stock-summary
Price to Book

13.36

Revenue and Profits:
Net Sales:
7,044 Cr
(Quarterly Results - Jun 2026)
Net Profit:
581 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.23%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.84%
0.12%
6.96%
6 Months
13.0%
0.13%
13.13%
1 Year
14.37%
0.26%
14.63%
2 Years
30.43%
0.57%
31.0%
3 Years
80.18%
1.08%
81.26%
4 Years
109.68%
1.62%
111.3%
5 Years
85.48%
1.73%
87.21%

Latest dividend: 10 per share ex-dividend date: Aug-14-2026

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Apollo Hospitals Gains 2.16%: 3 Key Factors Driving the Weekly Rally

Key Events This Week

24 Aug: Stock opened at Rs.8,700, modest gain despite Sensex dip

25 Aug: Upgraded to Strong Buy by MarketsMOJO; price surged 2.05%

26 Aug: Technical momentum shift confirmed; slight price dip

27 Aug: Sharp 13.75% open interest increase in derivatives

28 Aug: Week closes at Rs.8,845.70, up 0.46% on the day

Announcements stock-summary

Apollo Hospitals Enterprise Limited - Updates

22-Nov-2019 | Source : NSE

Apollo Hospitals Enterprise Limited has informed the Exchange regarding 'Sub: Certificate under Regulation 52(5) of SEBI (Listing Obligations

Apollo Hospitals Enterprise Limited - Analysts/Institutional Investor Meet/Con. Call Updates

14-Nov-2019 | Source : NSE

Apollo Hospitals Enterprise Limitedted has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

Apollo Hospitals Enterprise Limited - Shareholders meeting

22-Oct-2019 | Source : NSE

Apollo Hospitals Enterprise Limited has informed the Exchange regarding Proceedings of Court Convened General Meeting held on October 21, 2019. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Apollo Hospitals Enterprise Ltd. has declared 200% dividend, ex-date: 14 Aug 26

stock-summary
SPLITS

Apollo Hospitals Enterprise Ltd. has announced 5:10 stock split, ex-date: 02 Sep 10

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
16.82%
EBIT Growth (5y)
23.85%
EBIT to Interest (avg)
4.77
Debt to EBITDA (avg)
2.25
Net Debt to Equity (avg)
0.67
Sales to Capital Employed (avg)
1.46
Tax Ratio
24.50%
Dividend Payout Ratio
12.59%
Pledged Shares
2.49%
Institutional Holding
65.44%
ROCE (avg)
16.99%
ROE (avg)
15.76%

Valuation key factors

Factor
Value
P/E Ratio
60
Industry P/E
68
Price to Book Value
13.42
EV to EBIT
42.90
EV to EBITDA
33.31
EV to Capital Employed
8.43
EV to Sales
5.05
PEG Ratio
1.79
Dividend Yield
0.23%
ROCE (Latest)
18.27%
ROE (Latest)
20.63%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

FIIs

Pledged Promoter Holdings

2.4947

Mutual Funds

Held by 381 Schemes (17.33%)

FIIs

Held by 1202 FIIs (41.5%)

Promoter with highest holding

M/s. Pcr Investments Ltd (18.93%)

Highest Public shareholder

Sbi Nifty 50 Etf (2.32%)

Individual Investors Holdings

4.48%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 6.63% vs 1.98% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 9.71% vs 5.38% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7,043.50",
          "val2": "6,605.50",
          "chgp": "6.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,092.10",
          "val2": "1,011.00",
          "chgp": "8.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "120.40",
          "val2": "119.10",
          "chgp": "1.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "580.70",
          "val2": "529.30",
          "chgp": "9.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "15.51%",
          "val2": "15.31%",
          "chgp": "0.20%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 13.78% vs 15.22% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 33.04% vs 71.21% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "12,145.60",
          "val2": "10,674.90",
          "chgp": "13.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,793.00",
          "val2": "1,490.60",
          "chgp": "20.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "217.90",
          "val2": "233.90",
          "chgp": "-6.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "910.00",
          "val2": "684.00",
          "chgp": "33.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.76%",
          "val2": "13.96%",
          "chgp": "0.80%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 14.94% vs 14.78% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 33.70% vs 63.82% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18,623.00",
          "val2": "16,201.80",
          "chgp": "14.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,758.30",
          "val2": "2,252.10",
          "chgp": "22.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "330.50",
          "val2": "343.70",
          "chgp": "-3.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,412.30",
          "val2": "1,056.30",
          "chgp": "33.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.81%",
          "val2": "13.90%",
          "chgp": "0.91%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 15.76% vs 14.35% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 34.29% vs 60.91% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25,228.50",
          "val2": "21,794.00",
          "chgp": "15.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,769.30",
          "val2": "3,021.80",
          "chgp": "24.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "449.60",
          "val2": "458.50",
          "chgp": "-1.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,941.70",
          "val2": "1,445.90",
          "chgp": "34.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.94%",
          "val2": "13.87%",
          "chgp": "1.07%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQstock-summary

Jun'26
Mar'26
Change(%)
Net Sales
7,043.50
6,605.50
6.63%
Operating Profit (PBDIT) excl Other Income
1,092.10
1,011.00
8.02%
Interest
120.40
119.10
1.09%
Exceptional Items
0.00
0.00
Consolidate Net Profit
580.70
529.30
9.71%
Operating Profit Margin (Excl OI)
15.51%
15.31%
0.20%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2026 is 6.63% vs 1.98% in Mar 2026

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is 9.71% vs 5.38% in Mar 2026

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
12,145.60
10,674.90
13.78%
Operating Profit (PBDIT) excl Other Income
1,793.00
1,490.60
20.29%
Interest
217.90
233.90
-6.84%
Exceptional Items
0.00
0.00
Consolidate Net Profit
910.00
684.00
33.04%
Operating Profit Margin (Excl OI)
14.76%
13.96%
0.80%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 13.78% vs 15.22% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is 33.04% vs 71.21% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
18,623.00
16,201.80
14.94%
Operating Profit (PBDIT) excl Other Income
2,758.30
2,252.10
22.48%
Interest
330.50
343.70
-3.84%
Exceptional Items
-19.20
0.00
Consolidate Net Profit
1,412.30
1,056.30
33.70%
Operating Profit Margin (Excl OI)
14.81%
13.90%
0.91%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 14.94% vs 14.78% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is 33.70% vs 63.82% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
25,228.50
21,794.00
15.76%
Operating Profit (PBDIT) excl Other Income
3,769.30
3,021.80
24.74%
Interest
449.60
458.50
-1.94%
Exceptional Items
-19.20
0.00
Consolidate Net Profit
1,941.70
1,445.90
34.29%
Operating Profit Margin (Excl OI)
14.94%
13.87%
1.07%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 15.76% vs 14.35% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 34.29% vs 60.91% in Mar 2025

stock-summaryCompany CV
About Apollo Hospitals Enterprise Ltd. stock-summary
stock-summary
Apollo Hospitals Enterprise Ltd.
Large Cap
Hospital
Apollo Hospitals Enterprise Limited (AHEL) is a leading private sector healthcare provider in Asia. It has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics. AHEL's Hospitals are situated in Chennai, Hyderabad, Delhi, Ahmedabad, Pune, Chenganur, Coimbatore, Jaipur, Madurai, Anantpur, Nellore, Kurnool, Bhopal, Ranchi, Bilaspur and Bacheli.
Company Coordinates stock-summary
Company Details
No 19 Bishop Garden, Raja Annamalaipuram Chennai Tamil Nadu : 600028
stock-summary
Tel: 91-44-28290956/28293896
stock-summary
apolloshares@vsnl.net
Registrar Details
Integrated Enterprises (India) Ltd , II Floor , Kences Towers, No 1 Ramakrishna Street, North Usman Road, T Nagar, Chennai